Market capitalization | $516.10m |
Enterprise Value | $349.23m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.45 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-96.57m |
Free Cash Flow (TTM) Free Cash Flow | $-74.47m |
Cash position | $264.06m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
8 Analysts have issued a Celcuity Inc. forecast:
8 Analysts have issued a Celcuity Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.12 -0.12 |
25%
25%
|
|
EBITDA | -96 -96 |
66%
66%
|
EBIT (Operating Income) EBIT | -97 -97 |
66%
66%
|
Net Profit | -94 -94 |
66%
66%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Celcuity, Inc. is cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. Its proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Head office | United States |
CEO | Brian Sullivan |
Employees | 55 |
Founded | 2012 |
Website | www.celcuity.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.